Label: AMETHIA- ethinyl estradiol and levonorgestrel kit

  • NDC Code(s): 51862-047-01, 51862-047-91
  • Packager: Mayne Pharma Inc
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated March 1, 2024

If you are a consumer or patient please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use AMETHIA tablets safely and effectively. See full prescribing information for AMETHIA tablets. AMETHIA - Levonorgestrel/Ethinyl ...
  • Table of Contents
    Table of Contents
  • BOXED WARNING (What is this?)

    WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS

    Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke.[See Contraindications (4).]

    Close
  • 1. INDICATIONS AND USAGE
    AMETHIA tablets are indicated for use by women to prevent pregnancy.
  • 2. DOSAGE AND ADMINISTRATION
    Take one tablet by mouth at the same time every day. The dosage of AMETHIA tablets is one white tablet containing levonorgestrel and ethinyl estradiol daily for 84 consecutive days, followed by ...
  • 3. DOSAGE FORMS AND STRENGTHS
    AMETHIA tablets are available in Extended-Cycle Tablet Dispensers, each containing a 13-week supply of tablets: 84 white tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg ethinyl ...
  • 4. CONTRAINDICATIONS
    AMETHIA tablets are contraindicated in females who are known to have or develop the following conditions: A high risk of arterial or venous thrombotic diseases. Examples include women who are ...
  • 5. WARNINGS AND PRECAUTIONS
    5.1 Thrombotic and Other Vascular Events - Stop AMETHIA tablets if an arterial or deep venous thrombotic event occurs. Although the use of COCs increases the risk of venous thromboembolism ...
  • 6. ADVERSE REACTIONS
    The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling: Serious cardiovascular events and smoking - [see - Boxed Warningand ...
  • 7. DRUG INTERACTIONS
    No drug-drug interaction studies were conducted with AMETHIA tablets. 7.1 Changes in Contraceptive Effectiveness Associated with Co-Administration of Other Products - If a woman on hormonal ...
  • 8. USE IN SPECIFIC POPULATIONS
    8.1 Pregnancy - There is little or no increased risk of birth defects in women who inadvertently use COCs during early pregnancy. Epidemiologic studies and meta-analyses have not found an ...
  • 10. OVERDOSAGE
    There have been no reports of serious ill effects from overdose of oral contraceptives, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea.
  • 11. DESCRIPTION
    AMETHIA tablets are an extended-cycle oral contraceptive consisting of 84 white tablets each containing 0.15 mg of levonorgestrel, a synthetic progestogen and 0.03 mg of ethinyl estradiol, and 7 ...
  • 12. CLINICAL PHARMACOLOGY
    12.1 Mechanism of action - COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration ...
  • 13. NONCLINICAL TOXICOLOGY
    13.1. Carcinogenesis, Mutagenesis, Impairment of Fertility - [See - Warnings and Precautions (5.2, 5.3)].
  • 14. CLINICAL STUDIES
    In a 12-month, multicenter, randomized, open-label clinical trial, 1,006 women aged 18-40 were studied to assess the safety and efficacy of levonorgestrel/ethinyl estradiol tablets and ethinyl ...
  • 16. HOW SUPPLIED/STORAGE AND HANDLING
    16.1 How Supplied - AMETHIA tablets, 0.15mg/0.03 mg and 0.01 mg are available in Extended-Cycle Tablet Dispensers (NDC 51862-047-01), each containing a 13-week supply of tablets: 84 white ...
  • 17. PATIENT COUNSELING INFORMATION
    See - FDA-Approved Patient Labeling - Counsel patients that cigarette smoking increases the risk of serious cardiovascular events from COC use, and that women who are over 35 years old and ...
  • SPL UNCLASSIFIED SECTION
    Distributed by: Mayne Pharma - Greenville, NC 27834 - Manufactured by: Patheon, Inc. 2100 Syntex Court - Mississauga, Ontario L5N 7K9 Canada
  • PATIENT PACKAGE INSERT
    FDA-Approved Patient Labeling - Guide for Using - AMETHIA Levonorgestrel/Ethinyl Estradiol Tablets and Ethinyl Estradiol Tablets, 0.15 mg/0.03 mg and 0.01 mg - Revised August ...
  • SPL UNCLASSIFIED SECTION
    Distributed by: Mayne Pharma - Greenville, NC 27834 - Manufactured by: Patheon Inc. 2100 Syntex Court - Mississauga, Ontario L5N 7K9 - Canada - Revised: August 2022
  • PRINCIPAL DISPLAY PANEL - Kit Carton
    NDC 51862-047-91 - Amethia™ (Levonorgestrel/Ethinyl Estradiol Tablets - and Ethinyl Estradiol Tablets, 0.15 mg/0.03 mg and 0.01 mg) Contains 2 Extended-Cycle Tablet Dispensers ...
  • INGREDIENTS AND APPEARANCE
    Product Information